Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD

被引:110
作者
Koenecke, Christian [1 ]
Czeloth, Niklas [1 ]
Bubke, Anja [1 ]
Schmitz, Susanne [1 ]
Kissenpfennig, Adrien [2 ]
Malissen, Bernard [2 ]
Huehn, Jochen [3 ]
Ganser, Arnold [4 ]
Foerster, Reinhold [1 ]
Prinz, Immo [1 ]
机构
[1] Hannover Med Sch, Inst Immunol, D-30625 Hannover, Germany
[2] Univ Aix Marseille 2, INSERM, Ctr Immunol Marseille Luminy, Marseille, France
[3] Helmholtz Ctr Infect Res, Dept Expt Immunol, Braunschweig, Germany
[4] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, D-30625 Hannover, Germany
关键词
Animal models; Dendritic cells; Graft rejection; Regulatory T cells; REGULATORY T-CELLS; VERSUS-HOST-DISEASE; BONE-MARROW-TRANSPLANTATION; TGF-BETA; RETINOIC ACID; CUTTING EDGE; EXPRESSION; INDUCTION; DIFFERENTIATION; STIMULATION;
D O I
10.1002/eji.200939432
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Induced antigen-specific Foxp3(+) T cells (iTreg) are being discussed as a promising alternative to polyclonal natural Foxp3(+) T cells (nTreg) for cell-based therapies, particularly to achieve transplantation tolerance. Using Foxp3eGFP-reporter mice, we here establish an efficient protocol to induce and expand alloantigen-specific iTreg from Foxp3(-)CD4(+) T cells with cluster-disrupted DC. These iTreg were mainly CD62L(+) and showed efficient suppressive activity in vitro. However, in contrast to nTreg, adoptively transferred iTreg entirely failed to prevent lethal graft versus host disease (GVHD). Within irradiated recipients, the majority of adoptively transferred Foxp3(+) iTreg, but not Foxp3(+) nTreg quickly reverted to Foxp3(-)CD4(+) T cells. We therefore suggest that therapeutic approaches to treat GVHD should rely on nTreg, whereas the use of de novo alloantigen-induced iTreg should be handled with caution since the stability of the regulatory phenotype of the iTreg could be of major concern.
引用
收藏
页码:3091 / 3096
页数:6
相关论文
共 26 条
[21]   Efficient generation of human alloantigen-specific CD4+ regulatory T cells from naive precursors by CD40-activated B cells [J].
Tu, Wenwei ;
Lau, Yu-Lung ;
Zheng, Jian ;
Liu, Yinping ;
Chan, Ping-Lung ;
Mao, Huawei ;
Dionis, Kira ;
Schneider, Pascal ;
Lewis, David B. .
BLOOD, 2008, 112 (06) :2554-2562
[22]   Antigen-induced regulatory T cells [J].
Vigouroux, S ;
Yvon, E ;
Biagi, E ;
Brenner, MK .
BLOOD, 2004, 104 (01) :26-33
[23]   Th2 lymphoproliferative disorder of LatY136F mutant mice unfolds independently of TCR-MHC engagement and is insensitive to the action of Foxp3+ regulatory T cells [J].
Wang, Ying ;
Kissenpfennig, Adrien ;
Mingueneau, Michael ;
Richelme, Sylvie ;
Perrin, Pierre ;
Chevrier, Stephane ;
Genton, Celine ;
Lucas, Bruno ;
DiSanto, James P. ;
Acha-Orbea, Hans ;
Malissen, Bernard ;
Malissen, Marie .
JOURNAL OF IMMUNOLOGY, 2008, 180 (03) :1565-1575
[24]   Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+ CD25+ regulatory T cells [J].
Zhang, H ;
Chua, KS ;
Guimond, M ;
Kapoor, V ;
Brown, MV ;
Fleisher, TA ;
Long, LM ;
Bernstein, D ;
Hill, BJ ;
Douek, DC ;
Berzofsky, JA ;
Carter, CS ;
Read, EJ ;
Helman, LJ ;
Mackall, CL .
NATURE MEDICINE, 2005, 11 (11) :1238-1243
[25]   In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease [J].
Zhao, Dongchang ;
Zhang, Chunyan ;
Yi, Tangsheng ;
Lin, Chia-Lei ;
Todorov, Ivan ;
Kandeel, Fouad ;
Forman, Stephen ;
Zeng, Defu .
BLOOD, 2008, 112 (05) :2129-2138
[26]   Cutting edge:: Foxp3+CD4+CD25+ regulatory T cells induced by IL-2 and TGF-β are resistant to Th17 conversion by IL-6 [J].
Zheng, Song Guo ;
Wang, Juhua ;
Horwitz, David A. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (11) :7112-7116